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Abstract
Background: Recently many long-term prospective studies have involved serial collection and
storage of blood or tissue specimens. This has spurred nested case-control studies that involve
testing some specimens for various markers that might predict cancer. Until now there has been
little guidance in statistical design and analysis of these studies.
Methods: To develop statistical guidelines, we considered the purpose, the types of biases, and
the opportunities for extracting additional information.
Results: The following guidelines:
(1) For the clearest interpretation, statistics should be based on false and true positive rates – not
odds ratios or relative risks
(2) To avoid overdiagnosis bias, cases should be diagnosed as a result of symptoms rather than on
screening.
(3) To minimize selection bias, the spectrum of control conditions should be the same in study and
target screening populations.
(4) To extract additional information, criteria for a positive test should be based on combinations
of individual markers and changes in marker levels over time.
(5) To avoid overfitting, the criteria for a positive marker combination developed in a training
sample should be evaluated in a random test sample from the same study and, if possible, a
validation sample from another study.
(6) To identify biomarkers with true and false positive rates similar to mammography, the training,
test, and validation samples should each include at least 110 randomly selected subjects without
cancer and 70 subjects with cancer.
Conclusion: These guidelines ensure good practice in the design and analysis of nested case-
control studies of early detection biomarkers.
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Background
Most current methods of cancer early detection, such as
mammography or cervical cytology, are based on anatom-
ic changes in tissues or morphologic changes in cells. Re-
cently, various molecular markers, such as protein or
genetic changes have been proposed for cancer early de-
tection [1–4]. This has spurred many investigators with
long-term cohort studies to serially collect and store blood
or tissue specimens. The aim is to later perform a nested-
case control study, where specimens from subjects with a
particular type of cancer (cases) and specimens from a
random sample of subjects without the cancer (controls)
are tested for various molecular markers. Sometime this
sort of study is called a retrospective longitudinal study [6]
although retrospective longitudinal data could arise in
other ways, as well. Unlike cross-sectional study designs,
the markers are measured on specimens collected well be-
fore the onset of clinical disease in cases. This avoids the
potential confounding effect of the target disease on the
marker.
For example, in the ATBC (alpha-tocopherol, beta-caro-
tene) [7] and CARET [8] studies, subjects were rand-
omized to placebo or drug to in a long-term study to
determine the effect of the drug on lung cancer mortality.
During the course of the trial serum was serially collected
and stored in a biorepository. In a subsequent nested case-
control study, stored serum samples from all cases of pros-
tate cancer and a random sample of controls were tested
for prostate-specific antigen (PSA).
Importantly the nested case-control study of early detec-
tion biomarkers may be distinct from the original long-
term study from which serum were collected. It is de-
signed to answer a different question, it typically studies
subjects with a different disease, and it often ignores the
intervention in the original long-term study.
Methods
We had three considerations in formulating appropriate
guidelines. First we wanted to link the analysis to the goal
of study, namely, to help decide on further study of the bi-
omarker as a trigger for early intervention. Second we
wanted to minimize possible biases in the selection of cas-
es and the controls and in the investigation of many mark-
ers. Third, we wanted to extract as much information as
possible relevant to the evaluation.
Results
We offer the following guidelines for the design and anal-
ysis of nested case-control studies of early detection cancer
biomarkers.
1. For the clearest interpretation, statistics for binary
markers should be based on true and false positive rates
or predictive values based on the true prevalence – not
odds ratios, relative risks, or predictive values based on
the prevalence in the study
A promising marker should have a high degree of accuracy
in discriminating between subjects who are likely to get
cancer from those who are not. For a binary marker, which
is either positive or negative, the basic measures of this
type of accuracy are the true positive and false positive
rates. Consider the hypothetical data in the Table 1 from
a nested case-control study of early detection biomarkers.
The true positive rate (TPR), or the test sensitivity, is the
probability the marker is positive given cancer. The false
positive rate (FPR), or 1 – specificity, is the probability the
marker is positive given no cancer. In Table 1, TPR is esti-
mated by 80/100 = .80, and FPR is estimated by 10/1000
= 01. For a perfect test, TPR = 1 and the FPR = 0. There is
always a tradeoff between the TPR and FPR, so it is mean-
ingless to assess one without assessing the other. For ex-
ample, one could make the TPR equal to 1 simply by
classifying every subject as positive for cancer. But this
would be a poor classification rule because the FPR would
also be 1.
Guidelines for FPR and TPR
Because the underlying prevalence of cancer is so low in
average risk populations, for acceptable cancer screening
of asymptomatic people, the FPR should be very small [9].
As a starting point we recommend basing guidelines for
FPR and TPR on the FPR and TPR for mammography,
which, as discussed below, is FPR=.01 and TPR=.80. A
mammogram is analogous to a biomarker test for cancer
but there is extra information from various studies that
makes it useful for setting guidelines.
One reason for using FPR and TPR from mammography
as a standard is that, unlike biomarker measurements in
nested case-control studies, in mammography studies
there is a biopsy at the time of a positive test. This biopsy
is the gold standard for determining cancer status in sub-
jects with positive mammograms and is used for comput-
Table 1: Hypothetical data for a binary marker from a nested 
case-control study
Marker - Marker + Total
No cancer 990 10 1000
Cancer 20 80 100
True positive rate (TPR) = 80/100 = .80 = sensitivity False positive 
rate (FPR) = 10/1000 = .01 = 1 – specificityBMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/4
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ing TPR in a way not possible with biomarkers in nested
case-control studies. The TPR for mammography is the
probability of a positive biopsy as a direct result of mam-
mography in women with cancer and is estimated via
mathematical models or data collected after following
subjects not biopsied. As discussed in Baker and Pinsky
[10], estimates ranged from .74 to 1.00 with .80 a conserv-
ative value.
Importantly the estimated TPR for mammography is not
likely to be affected by overdiagnosis, which means that
some screening-detected cancers would never have caused
medical problems during the patient's life [11]. This
would make the biomarker appear more promising than
actually the case. Results from the HIP screening trial of
mammography and clinical self-examination [12] suggest
that if there were overdiagnosis with mammography, it
would be relatively small. At the time of the last breast
screening in the HIP trial, there were more cancers in the
group randomized to screening than in the controls. But
with further follow-up the number of cancers in the con-
trol group eventually equaled the number in the screened
group, which would not have occurred if there were sub-
stantial overdiagnosis.
A second reason for using FPR and TPR from mammogra-
phy is that, based on various randomized trials with can-
cer mortality endpoint, mammography is generally
considered an acceptable screening modality. The impli-
cation is that a similar FPR and TPR for a biomarker would
lead to an acceptable screening modality. For a particular
biomarker, these target values of FPR and TPR from mam-
mography may need modification depending on various
factors. One factor is the invasiveness of a follow-up pro-
cedure to investigate a positive test (e.g. needle biopsy of
the prostate to investigate an abnormal PSA versus
laparotomy to investigate an abnormal CA125). The more
invasive the follow-up procedure, the lower the FPR must
be to gain acceptance in practice. A second factor is addi-
tional work-up prior to a biopsy. If a positive biomarker is
unlikely to trigger additional diagnostic work-ups prior to
biopsy, a higher FPR might be acceptable.
One caveat when using FPR from mammography is to be
careful as to its definition. The restricted definition is the
probability of a positive biopsy as a direct result of mam-
mography in women without cancer. The less restricted
definition is the probability of a suspicious mammogram
warranting additional diagnostic follow-up of any type in
women without cancer. Typically nested-case control
studies of early detection biomarkers do not provide in-
formation on additional diagnostic follow-up. Therefore
they cannot be used to estimate a less restricted FPR in-
volving diagnostic follow-up. However, because nested
case-control biomarker studies provide data on cancer di-
agnosis, they can be used to estimate a more restricted FPR
based on unnecessary biopsies. Therefore the target FPR is
based on the more restricted definition of FPR in mam-
mography. For mammography the more restricted FPR is
estimated by the fraction of women screened by mam-
mography who received a biopsy in which no cancer was
detected. As discussed in Baker and Pinsky [10], estimates
of FPR from three studies ranged from .005 to .013 with a
middle value of around .010.
Inappropriateness of odds ratio and relative risk
When evaluating binary early detection markers, it is inap-
propriate to report an odds ratio or relative risk, as is com-
mon in epidemiology or clinical trials. Because an odds
ratio or relative risk is a single number, it does not capture
the tradeoff between correctly classifying cancer and in-
correctly classifying non-cancers. Also the odds ratio or
relative risk can lead to an overoptimistic impression of
the performance of an early detection test if the interpre-
tation is based on experience in epidemiology or clinical
trials. In the latter settings an odds ratio of 3 is often con-
sidered large. Much larger odds ratio are needed from ear-
ly detection tests for useful application in the screening
setting [13]. For example, for the target values of FPR = .01
and TPR = .80, the odds ratio equals (TPR ×  (1-FPR)/ ((1-
TPR) ×  FPR) = 396, as in Table 1.
Appropriate computation of predictive values
It is sometimes useful to use the FPR and TPR to compute
the predictive value negative (PVN), the probability of no
disease if the marker is negative, and the predictive value
positive (PVP), the probability of disease if the marker is
positive. For cancer screening, it is the PVP that is most im-
portant to the physician in clinical decision-making. Be-
cause the likelihood of any individual cancer type in an
asymptomatic person is nearly always very low, a negative
early detection test usually adds little information to the
clinical impression. The computation of the PVN and PVP
depend on the prevalence of cancer as well as on the FPR
and the TPR, as shown below,
PVP = (TPR ×  prevalence) / (TPR ×  prevalence + FPR (1-
prevalence))
PVN = (1-FPR) ×  (1-prevalence) / ((1-TPR) ×  prevalence +
(1-FPR) (1-prevalence))
When the prevalence is small, as with cancer screening, a
small absolute change in FPR, but not TPR, can have a
large impact on the PVP. It is erroneous to directly com-
pute the prevalence from data in the nested case-control
study, as in Table 1, because the ratio of cases to controls
in the study is not the same as in the population. For ex-BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/4
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ample suppose FPR = .01, TPR = .80, and prevalence =
.003. We obtain,
PVP = = (.8 ×  .003) /(.8 ×  .003 + .01 .997)= .19
PVN = (.99 ×  .997) / (.2 ×  .003 + .99 ×  .997) = .999
If we had incorrectly substituted the apparent prevalence
in Table 1 of 100/1100 = .091, we would have incorrectly
computed PVP = .89 and PVN = .980. For this reason, cal-
culation and reporting of PVP and PVN using only data
from a nested case-control study is not useful or appropri-
ate.
Extension to ordered categories via ROC curves
Many markers for the early detection of cancer can be re-
ported as ordered categories. Some markers, such as spu-
tum cytology, inherently involve ordered categories, such
as no evidence of cancer, slight atypia, moderate atypia,
severe atypia, and frank cancer. Other markers, such as
PSA, involve a continuous measure for which higher val-
ues indicate a greater probability of cancer. Dividing these
continuous measures into ranges (either based on prede-
termined values or percentiles) gives ordered categories.
With ordered categories, the statistics should still be based
on FPR and TPR. Each ordered category is a possible cut-
point, where values equal to or higher than the cutpoint
are called positive and values lower than the cutpoint are
called negative. For each cutpoint, one can compute FPR
and TPR (Table 2) and generate a receiver-operating char-
acteristic (ROC) curve, which is a plot of TPR versus FPR
for the various pairs [14]. (See Figure 1). The higher and
farther left the points on the ROC curve the better the test
performance. As mentioned previously, acceptable cancer
screening requires very small false positive rates. There-
fore, for evaluating cancer biomarkers, we are only inter-
ested in the leftmost sliver of the ROC curve in Figure 1.
2. To avoid overdiagnosis bias, cases should be diag-
nosed as a result of symptoms rather than on screening
For the TPR in the biomarker study to reflect the true TPR,
cases should be diagnosed as a result of symptoms rather
than on screening. For example in the study of PSA in the
ATBC trial [7], cases were subjects diagnosed with prostate
cancer as a result of symptoms. If the prostate cancer cases
were detected as the result of screening, say with ultra-
sound, the TPR could be artificially elevated if there were
overdiagnosis, as previously discussed.
3. To minimized selection bias, the spectrum of control
conditions should be the same in study and target
screening populations
For the FPR in the nested case-control study to reflect the
true FPR in the target population, the spectrum of control
conditions should be the same as in the target population.
By control conditions, we mean characteristics of the pop-
ulation, such as the presence of other diseases or certain
known risk factors that could elevate the false positive
rate.
The spectrum of conditions could differ considerably if
the retrospective biomarker study were embedded in a
Table 2: Hypothetical Data for an Ordered Marker From a Nest-
ed Case-Control Design
12345
No cancer 960 20 10 8 2 1000
C a n c e r 0 1 01 02 06 0 1 0 0
For cutpoint 4, the true positive rate is (20+60)/100 = .80 For cut-
point 4, the false positive rate is (8 + 2)/1000 = .01
Figure 1
ROC curve derived from hypothetical data in Table 2.
Because acceptable cancer screening requires a very small
false positive rate (FPR) and a reasonable true positive rate
(TPR), only the four points farthest to the left are relevant
for biomarker evaluation.BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/4
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randomized trial with strict eligibility requirements. For
example, consider a biomarker for the early detection of
lung cancer where the data comes from a biorepository
arising from a randomized trial of healthy subjects. It
would be inappropriate to apply the results to a popula-
tion with a high prevalence of chronic obstructive lung
disease, bronchitis, or viral pnuemonitis because these
conditions could increase the number of positive readings
in subjects without lung cancer. Because FPR is very small
for screening to be acceptable, this spectrum bias could
have important consequences in a clinical application.
It would not always be possible to identify all relevant
control conditions, but to the extent possible, the control
conditions should be similar in both populations.
4. To extract additional information, criteria for a posi-
tive test should be based on combinations of individual
markers and changes in marker levels over time
Data from multiple markers present an opportunity to ex-
tract potentially valuable information not available by an-
alyzing markers separately. Consider the hypothetical
data in Table 3. The left side corresponds to subjects with-
out cancer, and the right corresponds to subjects with can-
cer. In our idealized circumstance, markers A and B are
independent for subjects without cancer and are perfectly
correlated for subjects with cancer. The indicated region
for A = 2 or A = 3 and B = 2 or B = 3 designates a positive
test that has FPR = .04 and the TPR = .80. Suppose that
marker A and marker B were evaluated separately. The in-
dicated region corresponding to A only, namely A = 2 or
A = 3 and the indicated region corresponding to B only,
namely B = 2 and B = 3, each designates a positive test that
has FPR=. 20 and TPR=. 80. Thus, in this particular exam-
ple, the combination of markers leads to a much better
test than the separate markers, with a smaller FPR (.04 ver-
sus .20) for the same TPR of .80. One could create a simi-
lar example with any number of marker levels. For an
ideal test in which FPR = 0 and TPR = 1, the region would
encompass all subjects with cancer but no subjects with-
out cancer.
A real application of how marker combinations provide
extra information comes from a recent study by Mok et al
[15] on CA125 and Prostasin as markers for ovarian can-
cer. Although the data are not from a nested case-control
study and have not been validated in subsequent studies,
they are useful for illustration. Based on Figure 5 of Mok
et al [15] with approximate values for the outpoints, we
investigated regions with FPR=.02. The combination for a
positive test of CA 125 greater than or equal to 40 U/ml
and Prostasin greater than or equal to 5 µg/ml had FPR =
.02 and TPR = .92. Evaluating CA 125 alone, the criterion
for a positive test of CA 125 greater than 80 U/ml had
FPR=.02 and TPR =.78. Evaluating Prostasin alone, the cri-
terion for a positive test of Prostasin greater than 15 µg/ml
had FPR=. 02 and TPR=. 32. Thus, in this real example, the
combination of markers led to a better test than the sepa-
rate markers, with a larger TPR (.92 versus .78 or .32) for
the same FPR of .02.
To more generally compare performance of a combina-
tion of markers with a single marker, we need to compare
ROC curves. Creating an ROC curve from a combination
of markers is different from creating an ROC curve from a
single marker. With a combination of markers, the
number of possible regions, as in Table 3 a, for calling a
marker positive is extremely large. Some choices of re-
gions correspond to AND rules, for example A>1 and B>1,
as in Table 3 a. Some choices of regions correspond to OR
rules, for example A>2 or B>2. Other choices are also pos-
sible, but for biological reasons, one would usually re-
quire all regions to be contiguous. A plot of the FPR and
Table 3: Hypothetical data for two ordered markers, A and B
Subjects without cancer (N = 1000) Subjects with cancer (N = 100)
A = 1 A = 2 A = 3 B only A = 1 A = 2 A = 3 B only
B = 1 640 80 80 800 20 0 0 20
B = 2 80 10a 10a 100e 0 20b 0b 20f
B = 3 80 10a 10a 100e 0 0b 60b 60f
A only 800 100c 100c 20 20d 60d
For A and B combined; aFalse positive rate (FPR) of indicated region (10+10+10+10)/1000=. 04; bTrue positive rate (TPR) of indicated region = 
(20 +0+0+60)/100=. 80 For A only; cFalse positive rate (FPR) of indicated region =(100+100)/1000=. 20; dTrue positive rate (TPR) of indicated 
region = (20+60)/100=. 80 For B only; eFalse positive rate (FPR) of indicated region =(100+100)/1000= .20; fTrue positive rate (TPR) of indicated 
region = (20+60)/100=.80BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/4
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TPR for each region would lead to a cloud of points, rather
than the smooth curve in Figure 1. To create the best ROC
curve, one should select those points that are highest and
farthest to the left, which is generally all that would need
to be presented and only for small false positive rates. For
complicated situations, Baker [16] proposed an algorithm
to select the regions creating the best ROC curve without
the need to enumerate all the regions. Mathematically, in
any sample of data, the best ROC curve for a combination
of markers must be as good or better than the ROC curve
for any of the markers evaluated separately. The reason is
that the set of possible regions for calling a combination
of markers positive includes as a special case the regions
for calling any single marker positive.
Alternative approaches that do not directly optimize the
ROC curve include linear logistic regression or linear dis-
criminant analysis [17], which choose regions based on
linear combinations of the markers, and neural networks
[18], which choose regions in a very complicated nonlin-
ear manner. Due to the potential for overfitting (to fol-
low), it is not possible to make a blanket statement as to
which approach for choosing regions is best. If one takes
the set of regions for calling a combination positive that
gives a good ROC curve in a random sample of data, it
may give a poor ROC curve in another random sample of
the data, simply due to selecting chance patterns in the
first sample. As discussed in the section on overfitting, this
motivates splitting the data into two random samples,
training and test, and using the regions from the training
sample to compute the definitive ROC curve based on
data in the test sample.
Changes in marker values over time also provide poten-
tially valuable information not available when examining
markers at a single time point. With marker measure-
ments at two different times per subject (and approxi-
mately the same interval between times), a common
summary measure is the slope. If investigators believe that
both slope and baseline level predict cancer, the combina-
tion can be evaluated using the previously discussed
methods for evaluating multiple markers, namely, treat-
ing baseline level and slope as two "separate" markers.
With measurements at more than two times per subject,
investigators may identify a more complicated feature,
such as whether or not there is a sudden increase in mark-
er levels [19].
When biomarker measurements occur at regular time in-
tervals (and allowing different numbers of measurements
for each subject), one can estimate TPR and FPR by using
a first order Markov chain in reverse time, as described by
Baker and Tockman [20] for the analysis of precancerous
lesions for lung cancer.
5. To avoid overfitting, the criteria for a positive marker
combination developed in a training sample should be
evaluated in a random test sample from the same study
and, if possible, a validation sample from another
study.
With a single marker and a large number of subjects, there
is usually no concern with overfitting. However with
many combinations of markers, overfitting could invali-
date results. Overfitting is often associated with step-wise
regression models [21] but it can occur in other situations
as well. Overfitting of a larger number of markers to a rel-
atively small number of subjects produces a model that is
overly sensitive to chance fluctuations in the data. As a
simple example, overfitting occurs when a sports an-
nouncer reports that a baseball player had a very high bat-
ting average against left-handed pitchers in ballpark X
over the past month. This average is not very reliable for
future predictions because the particular set of factors,
left-handed pitchers and ballpark X, were selected to give
a high average. In reality the high average is more likely
the result of chance factors that coincided with left hand-
ed pitchers at ballpark X during that particular month.
One way to adjust for overfitting is to apply the factors in
another sample not used for initial reporting. The first
sample is known as the training sample, and the second
sample is known as the test sample. For example, the pre-
diction of the average against left handed pitchers in the
ballpark X could be tested on data from a different month.
Similarly, a standard statistical approach to adjust for
overfitting is to randomly split the data into a training and
test samples. This is called the split-sample approach.
Promising marker combinations are identified in the
training sample, but more reliable FPR and TPR measure-
ments are made in the test sample because it involves dif-
ferent data. Baker [16] used the split-sample approach to
evaluate the performance of four markers for prostate can-
cer.
More sophisticated adjustments for overfitting include
cross-validation and bootstrapping. Suppose the interest
lies in a single statistic, such as the area under the part of
the ROC curve corresponding to a small FPR. In a typical
cross-validation analysis (i) the data are randomly split
into ten samples each with 10% of the data, (ii) one of the
10% samples is deleted, (iii) the statistic is computed by
applying the classification rule recalculated from the re-
maining 90% of the sample to the deleted 10% sample
and (iv) an average is taken of the statistic over all ten 10%
samples [22]. Although one could use a different fraction
than 10%, ROC computation it is not possible with the
most extreme version of cross-validation that involves
leaving out one subject at a time. With bootstrapping, (i)
the entire data set is resampled with replacement many
times, (ii) on each resampling the statistics is computed,BMC Medical Research Methodology 2002, 2 http://www.biomedcentral.com/1471-2288/2/4
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and (iii) the statistics from each resampling are combined
in a special way [22]. In a recent study comparing these
adjustments with other types of statistics in a different set-
ting, Steyerberg et al [22] found that the split-sample ap-
proach tended to underestimate performance, cross-
validation performed poorly on some statistics that were
not normally distributed, and bootstrapping performed
best overall. For our purposes of estimating an entire ROC
curve rather than a summary statistic, more research is
needed for cross-validation and bootstrapping, as it is not
clear how best to combine ROC curves over different sam-
ples.
Regardless of the method used to adjust for overfitting in
forming a classification rule, to obtain the most reliable
FPR and TPR measurements, the classification rule should
ideally be evaluated in a validation sample from a different
study, as in Baker [16].
6. To identify biomarkers with true and false positive
rates similar to mammography, the training, test, and
validation samples should each include at least 110 ran-
domly selected subjects without cancer and 70 subjects
with cancer (as based on FPR and TPR for mammogra-
phy)
The sample size is based on the need to determine if the
biomarker is sufficiently promising for investigation as a
trigger for early intervention in a future trial. As discussed
previously, based on considerations from mammography,
our target values are FPR = .01 and TPR= .80. In most sit-
uations, we think it would be of interest to specify a 95%
confidence interval for TPR of (.70, .90). Using a normal
approximation the target standard error is approximately
.05. Setting the standard error of TPR, TPR ×  (1-TPR) /
(square root of n), equal to .05 and solving for the sample
size n, we obtain n= 64, which we round up to 70. In ad-
dition we think that in most situations the largest reason-
able value of FPR would be .03 which is 3 times the
number of false positives as with mammography screen-
ing. Because FPR is so small, we do not use a normal ap-
proximation. We specify a sample size of n = 110, so that
under the binomial distribution with FPR=.01, the upper
2.5% bound equals .03 ×  110. Strictly, these sample sizes
apply only after a single criterion for a positive test has
been identified. For a training sample, one might consider
larger sample sizes.
Conclusion
A major advantage of nested case-control studies for early
detection biomarkers is that they can be done quickly if
serum from a long-term study has been stored in a biore-
pository. Importantly the retrospective aspect does not
compromise the validity. There are none of the usual
problems with retrospective studies such as recall bias.
Thus we anticipate that in the coming years, there will be
many reports in literature from studies of this design.
These guidelines should greatly help investigators design
and analyze nested case-control studies for early detection
biomarkers and help readers of the literature to interpret
them. It bears emphasis that these studies do not prove
clinical efficacy of the markers. Rather, they suggest which
markers or marker combinations are the most promising
candidates for further study as a trigger for early interven-
tion in definitive trials with cancer-mortality endpoints.
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